NexImmune, Inc. has been notified by Nasdaq that its shares will be delisted from the Nasdaq Capital Market due to the company being identified as a 'public shell.' The delisting notice, dated July 10, 2024, follows a previous warning from December 1, 2023, and a hearing held on February 29, 2024, where NexImmune was granted an exception until May 28, 2024, to comply with listing rules. Trading of NexImmune's common stock is set to be suspended on July 12, 2024. Concurrently, NexImmune convened a special meeting of stockholders on July 11, 2024, to approve the liquidation and dissolution of the company, which was adjourned without resolution. The meeting is rescheduled for July 19, 2024, to allow the company time to explore alternative strategies to maximize asset value. The company continues to solicit votes from stockholders for the upcoming reconvened meeting.

NexImmune, Inc. has been notified by Nasdaq that its shares will be delisted from the Nasdaq Capital Market due to the company being identified as a 'public shell.' The delisting notice, dated July 10, 2024, follows a previous warning from December 1, 2023, and a hearing held on February 29, 2024, where NexImmune was granted an exception until May 28, 2024, to comply with listing rules. Trading of NexImmune's common stock is set to be suspended on July 12, 2024. Concurrently, NexImmune convened a special meeting of stockholders on July 11, 2024, to approve the liquidation and dissolution of the company, which was adjourned without resolution. The meeting is rescheduled for July 19, 2024, to allow the company time to explore alternative strategies to maximize asset value. The company continues to solicit votes from stockholders for the upcoming reconvened meeting.